Cassandra A. Hathaway

May 23, 2024 | jamanetwork.com | Jessica Y. Islam |Cassandra A. Hathaway |Emma Hume |Julie Hallanger-Johnson

Characteristics of Patients With Cancer and COVID-19 Who Discontinued Cancer Treatment Introduction The COVID-19 pandemic disrupted access to cancer treatment.1 COVID-19–related disruptions in treatment may have disproportionately affected individuals who experienced a high burden of COVID-19–related disease.1 Our objective was to evaluate cancer treatment discontinuations (TDs) among patients with cancer who received a diagnosis of SARS-CoV-2 during their cancer treatment planning. Methods...

May 20, 2024 | jamanetwork.com | Jessica Y. Islam |Cassandra A. Hathaway |Julie Hallanger-Johnson |Emma Hume

Key PointsQuestion  Among patients with cancer and a confirmed SARS-CoV-2 infection identified during their cancer treatment planning, were there racial and ethnic differences in cancer treatment continuity throughout different waves of the COVID-19 pandemic?

Apr 25, 2023 | onclive.com | Cassandra A. Hathaway

Cassandra A. Hathaway, MD, oncologist, Moffitt Cancer Center, discusses the rationale for investigating the association between distress, such as depression, and the tumor immune microenvironment (TME) in patients with ovarian cancer. Previous research has connected depression with an increased risk of ovarian cancer, Hathaway begins. Accordingly, it was hypothesized that this may be attributed to norepinephrine, Hathaway notes, adding that previous studies have investigated this connection.